PMPeierdun Mijiti

Peierdun Mijiti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peierdun Mijiti has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Kaibinuer Tuoheti

    Department of Epidemiology and Biostatistics, School of Public Health, Xinjiang Medical University, Urumqi, Xinjiang, China

    2 shared publications
  • Qi Shuang

    Department of Epidemiology and Biostatistics, School of Public Health, Xinjiang Medical University, Urumqi, Xinjiang, China

    2 shared publications
  • Wei Jingjing

    School of Public Health, Xinjiang Medical University, Urumqi, China

    2 shared publications
  • Ye Lixia

    Department of Epidemiology and Biostatistics, School of Public Health, Xinjiang Medical University, Urumqi, Xinjiang, China

    2 shared publications
  • Chen Jihong

    Department of Nephrology, Affiliated Bao’an Hospital of Shenzhen, The Second School of Clinical Medicine, Southern Medical University, Shenzhen, Guangdong, 518101, People’s Republic of China

    1 shared publication
  • Guzalinuer Aizezi

    Department of Epidemiology and Biostatistics, School of Public Health, Xinjiang Medical University, Urumqi, Xinjiang, China

    1 shared publication

Latest Publications

  • Open Access

    Trends in incidence, mortality, and DALYs of cystic echinococcosis in Central Asia from 1992 to 2021: an age-period-cohort analysis

    by Wulan Talafuhan, Kaibinuer Tuoheti, Ye Lixia, Qi Shuang, Mieyier Yeerjiang, Guzalinuer Aizezi, Wei Jingjing, Peierdun Mijiti

    Background: Cystic echinococcosis (CE) is widespread globally but imposes a particularly heavy burden in Central Asia. Despite control measures, disease management remains suboptimal in this region. This study analyzed trends in CE incidence, mortality, and disability-adjusted life years (DALYs) from 1992 to 2021 in Central Asia; compared them with global data; and explored variations by gender, age group, and country to identify critical factors in disease control.Methods: Using data from the Global Burden of Disease Study 2021 (GBD 2021), we analyzed long-term trends in the incidence, mortality, and DALY rates of CE in Central Asia. The joinpoint regression model was employed to calculate the annual percentage change (APC) and average APC (AAPC) to identify shifts in disease trends. Additionally, an age-period-cohort model was used to assess the impact of various age groups, periods, and birth cohorts on the disease burden.Results: The number of CE cases increased by 52.13% in Central Asia, while deaths decreased by 57.35%; DALYs decreased only slightly by 10.75%. From 1992 to 2021, CE incidence showed an increasing trend until 2010, then rapidly declined until 2015, and then gradually increased thereafter. The highest incidence rates were among middle-aged and older adult populations. Although mortality and DALY rates decreased across all age groups, the decline was less than the global trend. Gender analysis showed that the incidence rate was significantly higher in males than in females.Conclusion: Although there have been improvements in the CE disease burden in some Central Asian countries, the overall burden remains significant. This study highlights the importance of considering gender, age, and country-specific disease burdens when formulating public health policies. Future research should continue to monitor these trends and explore targeted prevention strategies within diverse socioeconomic contexts, such as integrating regional socioeconomic factors and public health resources.


  • Open Access

    A network approach to investigating the inter-relationship between health-related quality of life dimensions and depression in 1735 Chinese patients with heterogeneous cancers

    by Sulaiman Muhetaer, Peierdun Mijiti, Kaibinuer Aierken, Huang Ziyin, Wulan Talapuhan, Kaibinuer Tuoheti, Ye Lixia, Qi Shuang, Wei Jingjing

    Background: We aimed to explore the inter-connection between depression and HRQOL dimensions in cancer patients using a network approach, which might provide new insights for precise interventions to improve cancer patients’ overall HRQOL.Methods: Between June 1, 2016, and August 31, 2017, a total of 1735 eligible patients with heterogeneous types of cancer were recruited. The Zung Self-Rating Depression Scale (SDS) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) were used to measure patients’ depression status and HRQOL, respectively. A regularized partial correlation network was established. Central and bridge symptoms/functions were identified using expected influence and bridge expected influence. A directed acyclic graph (DAG) was used to explore the possible causal relationship between depression and HRQOL dimensions.Results: In this study, depression and 15 dimensions of the EORTC-QLQ-C30 scale were highly inter-correlated and could be represented as a network. We found that nearly two-thirds of cancer patients experienced various degrees of depression, and depression was consistently the central symptom in the network, in addition to nausea/vomiting, pain, and physical function. DAG and bridge symptoms indicated that depression might influence overall HRQOL in cancer patients mainly through emotional function, pain, physical function, and sleeplessness, particularly in cancer patients with moderate-to-severe depression. The disparity in network structures between mild and moderate-to-severe depression suggested that the relationship between depression and HRQOL dimensions might be bidirectional.Conclusion: The prevalence of depression remained high in Chinese patients with cancer, and depression may influence various symptoms and functions within the HRQOL network. Screening and early treatment of depression were warranted to improve the overall HRQOL of cancer patients, in addition to adequate treatment of pain and nausea/vomiting and improvement in physical function.


  • Open Access

    Predictors and Trends of MDR/RR-TB in Shenzhen China: A Retrospective 2012–2020 Period Analysis

    by Ji Lecai, Peierdun Mijiti, Hong Chuangyue, Li Mingzhen, Gao Qian, Tan Weiguo, Chen Jihong

    Purpose: We analyzed the trends and predictors of multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis (TB) in culture-positive cases in Shenzhen during 2012– 2020, after the implementation of improved strategies (scale-up molecular drug susceptibility testing [mDST], expansion of DST eligibility, and generous reimbursement of MDR-TB outpatient care costs). Materials and Methods: We retrospectively extracted and analyzed data from the TB Information System on drug-resistant pulmonary tuberculosis diagnosed in Shenzhen during the 2012– 2020 period. We analyzed trends in RR- and MDR-TB rates in new cases during 2012– 2018 and 2018– 2020 periods, and among previously-treated cases during 2012– 2017 and 2017– 2020 periods, using Cochran-Armitage tests. We generated multivariate logistic regression models to analyze demographic predictors of MDR/RR-TB rates. Results: We found 21,367 positive mycobacterial cultures in Shenzhen during the 2012– 2020 period, and 19,951 (93.4%) were identified as Mycobacterium tuberculosis and had DST results (92.0% of those were mDST-based). Of these patients with DST results, 1630 (8.2%) were RR-TB, and 1142 (5.7%) were MDR-TB. Of the RR-TB, 70% were MDR-TB. The MDR/RR-TB rate in new TB cases increased significantly during the 2012– 2018 period (Ptrend < 0.05), but it decreased in the 2018– 2020 period (Ptrend > 0.05, with a significant trend for MDR-TB). Among previously treated cases, the temporal MDR/RR-TB rate trends did not differ significantly (Ptrend > 0.05). Our multivariate analysis showed that age younger than 30 years, housework service/unemployment, local residency, and previous TB treatment were all predictors of MDR/RR-TB. The percentage of patients with MDR-TB on treatment increased from 49.4% in 2012 to 70.5% in 2020. The treatment success rate of patients with MDR-TB during the 2012– 2018 period was 71%. Conclusion: During the study period in Shenzhen, the cases of MDR/RR-TB were detected, and the treatment enrollment increased and the MDR-TB rates decreased gradually after 2017. Decreasing trends may reflect the efficacy of improved strategies; however, their long-term impact on the MDR-TB burden remains to be investigated. The predictors of MDR-TB identified in our study should be considered when developing targeted MDR-TB control strategies.